Alembic Pharmaceuticals Limited has informed the Exchange regarding Board meeting held on November 04, 2025.
APLLTD · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Alembic Pharmaceuticals' Board, meeting on November 4, 2025, approved unaudited consolidated and standalone financial results for Q2 and H1 FY26 (quarter and half-year ended September 30, 2025). Consolidated revenue from operations rose to Rs. 1,910.15 crore in Q2 FY26, up about 16% from Rs. 1,647.98 crore in Q2 FY25; H1 FY26 revenue grew to Rs. 3,620.87 crore vs Rs. 3,209.71 crore. Consolidated profit after tax for H1 FY26 stood at Rs. 337.34 crore vs Rs. 287.69 crore in H1 FY25, an increase of around 17%. Standalone operating margin expanded meaningfully from about 14.8% in Q2 FY25 to about 17.5% in Q2 FY26. The company also disclosed the acquisition of UK-based Utility Therapeutics via its US subsidiary for USD 25 million (Rs. 221.97 crore), recognized as an intangible asset. Statutory auditors KKC & Associates LLP issued an unqualified review report.
Positive quarter with double-digit revenue growth, healthy PAT expansion, and improving margins – supportive for shareholders. However, investors should note the change of statutory auditor (from K C Mehta & Co LLP to KKC & Associates LLP) and monitor integration of the Utility Therapeutics acquisition.